Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 13/30237% above fair value
$111.60−2.62 (-2.29%)
Close on Nov 13, 2026Market cap $7.00BP/E –Yield –
Twist Bioscience cash
Cash and short-term investments held at the end of each period.
Twist Bioscience's cash was $166.84M at Jun 30, 2026. For fiscal 2025 it was $232.43M, down 16.8% from the year before. The highest annual figure on record is $504.97M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $232.43M | -16.8% |
| FY2024 | Sep 30, 2024 | $279.22M | -17.0% |
| FY2023 | Sep 30, 2023 | $336.40M | -33.4% |
| FY2022 | Sep 30, 2022 | $504.97M | +5.7% |
| FY2021 | Sep 30, 2021 | $477.86M | +64.8% |
| FY2020 | Sep 30, 2020 | $290.00M | +110.0% |
| FY2019 | Sep 30, 2019 | $138.11M | +71.0% |
| FY2018 | Sep 30, 2018 | $80.76M | +155.8% |
| FY2017 | Sep 30, 2017 | $31.57M | +8.6% |
| FY2016 | Sep 30, 2016 | $29.06M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $166.84M | -34.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $171.67M | -33.9% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $197.95M | -27.6% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $232.43M | -16.8% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $253.33M | -12.5% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $259.66M | -11.5% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $273.48M | -12.1% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $279.22M | -17.0% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $289.40M | -19.8% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $293.30M | -24.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $311.10M | -29.1% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $336.40M | -33.4% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $360.86M | -31.8% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $387.66M | -32.6% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $438.71M | +44.6% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $504.97M | +5.7% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $529.16M | +1.6% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $575.43M | +3.3% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $303.43M | -48.5% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $477.86M | +64.8% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $520.94M | +66.7% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $557.19M | +141.5% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $588.82M | +466.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $290.00M | +110.0% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $312.42M | +92.2% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $230.73M | +119.5% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $104.03M | -20.5% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $138.11M | +71.0% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $162.56M | +78.4% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $105.12M | +33.7% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $130.80M | +397.5% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $80.76M | +155.8% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $91.10M | +213.5% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $78.63M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $26.29M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $31.57M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $29.06M | – |
See a number that looks wrong?